Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Immune Reconstitution Syndrome

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – November 2011

  • Combivir (lamivudine/zidovudine) tablets
  • Emtriva (emtricitabine) Capsules and Oral Solution
  • Epivir(lamivudine) Tablets and Oral Solution
  • Epzicom (abacavir sulfate and lamivudine) Tablets
  • Retrovir  (zidovudine) IV Infusion, Capsules, Tablets, and Syrup
  • Trizivir (abacavir sulfate, lamivudine, and zidovudine) Tablets
  • Videx (didanosine) Pediatric Powder Oral Solution
  • Videx EC (didanosine, USP) Capsules
  • Viread (tenofovir disoproxil fumarate) Tablets
  • Zerit (stavudine) Capsules and Oral Solution
  • Ziagen (abacavir sulfate) Tablets and Oral Solution

 

Summary View

WARNINGS AND PRECAUTIONS

Immune Reconstitution Syndrome
  • Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiationof treatment.

 

-
-